DK3436019T3 - (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3436019T3
DK3436019T3 DK17776743.1T DK17776743T DK3436019T3 DK 3436019 T3 DK3436019 T3 DK 3436019T3 DK 17776743 T DK17776743 T DK 17776743T DK 3436019 T3 DK3436019 T3 DK 3436019T3
Authority
DK
Denmark
Prior art keywords
amino
fluortetrahydro
trichlorphenyl
purin
methylcyclohexane
Prior art date
Application number
DK17776743.1T
Other languages
English (en)
Inventor
Zheng Chen
Paul F Fernandez
Tracy L Gaebele
Lianfeng Huang
Matthew J Jackson
Matthew M Kreilein
Xiaoling Lu
Wenju Wu
Jean Xu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of DK3436019T3 publication Critical patent/DK3436019T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17776743.1T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf DK3436019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01
PCT/US2017/025289 WO2017173218A1 (en) 2016-04-01 2017-03-31 Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Publications (1)

Publication Number Publication Date
DK3436019T3 true DK3436019T3 (da) 2021-10-11

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17776743.1T DK3436019T3 (da) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf

Country Status (19)

Country Link
US (2) US10047090B2 (da)
EP (2) EP3845536A1 (da)
JP (1) JP6995058B2 (da)
CN (1) CN109819649B (da)
AU (1) AU2017240050B2 (da)
CA (1) CA3019105A1 (da)
CY (1) CY1124677T1 (da)
DK (1) DK3436019T3 (da)
ES (1) ES2895419T3 (da)
HR (1) HRP20211546T1 (da)
HU (1) HUE056631T2 (da)
LT (1) LT3436019T (da)
MX (1) MX379439B (da)
PL (1) PL3436019T3 (da)
PT (1) PT3436019T (da)
RS (1) RS62496B1 (da)
SI (1) SI3436019T1 (da)
SM (1) SMT202100604T1 (da)
WO (1) WO2017173218A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
BR112018070163A2 (pt) * 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
EP3798224B1 (en) 2016-06-21 2025-03-19 Assia Chemical Industries LTD Solid state forms of ixazomib citrate
BR112020006599B1 (pt) 2017-10-04 2024-02-20 Celgene Corporation Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida
US10590136B2 (en) * 2017-10-04 2020-03-17 Celgene Corporation Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4237431A1 (en) * 2020-12-15 2023-09-06 Centre National de la Recherche Scientifique Sqstm1 and its use in cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
JP2009516707A (ja) 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CN101568544B (zh) 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
PT2279731E (pt) 2008-04-23 2013-08-30 Farmasierra Mfg S L Composição farmacêutica melhorada contendo ibuprofeno e codeína
US20130034495A1 (en) * 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
KR20230035424A (ko) * 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento

Also Published As

Publication number Publication date
EP3436019A4 (en) 2019-08-28
US20170283418A1 (en) 2017-10-05
ES2895419T3 (es) 2022-02-21
US10513519B2 (en) 2019-12-24
CA3019105A1 (en) 2017-10-05
EP3436019A1 (en) 2019-02-06
JP2019515889A (ja) 2019-06-13
SMT202100604T1 (it) 2021-11-12
MX379439B (es) 2025-03-10
CY1124677T1 (el) 2022-07-22
PL3436019T3 (pl) 2022-01-10
WO2017173218A1 (en) 2017-10-05
US10047090B2 (en) 2018-08-14
EP3845536A1 (en) 2021-07-07
HRP20211546T1 (hr) 2022-01-07
SI3436019T1 (sl) 2021-12-31
JP6995058B2 (ja) 2022-02-21
PT3436019T (pt) 2021-11-04
CN109819649B (zh) 2023-02-28
CN109819649A (zh) 2019-05-28
AU2017240050A1 (en) 2018-10-11
AU2017240050B2 (en) 2021-12-16
RS62496B1 (sr) 2021-11-30
MX2018011970A (es) 2019-05-20
HUE056631T2 (hu) 2022-02-28
EP3436019B1 (en) 2021-07-28
LT3436019T (lt) 2021-10-25
US20180362529A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
HUE056631T2 (hu) (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik
EP3494903C0 (en) VERTEBRAL PROCESS FORCEPS
DK4279084T3 (da) Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi
DK3638243T3 (da) Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3882357T3 (da) Fremgangsmåder og sammensætninger til analyse af nukleinsyrer
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3201336T3 (da) Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
DK3232806T3 (da) Opløsning af denatureret ærteprotein og anvendelser deraf til dannelse af mikropartikler
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3484865T3 (da) Somatostatinmodulatorer og anvendelser deraf
DK3630977T3 (da) Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3555391T3 (da) Bærbart multifunktionelt system og fremgangsmåde til fremstilling heraf
DK3245193T3 (da) Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3589748T3 (da) Nukleinsyremodifikation og identifikationsfremgangsmåde
DK3309538T3 (da) Optisk system og fremgangsmåde til spektroskopi
DK3484599T3 (da) Oprensningsfremgangsmåde og anvendelser deraf
DK3577279T3 (da) Injektionsredskab og fremgangsmåde til injektion